Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Lucid Diagnostics Inc.NASDAQ: LUCD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables grows, but more slowly than its trailing trend
Q1 FY2026 accounts receivables of $46K (cash outflow) rose 187.5% year over year, behind the +5158.3% change in trailing-twelve-month accounts receivables. Sequentially, it fell 52.1% from the prior quarter.
Context
- Accounts receivables amounted to 12.8% of revenue in FY2025, up 12.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +187.5% toward the trailing-twelve-month pace of +5158.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (601K) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (601K) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (28K) | -115.3% |
| FY2022 | 2022-12-31 | 183K | +191.5% |
| FY2021 | 2021-12-31 | (200K) | — |
Accounts Receivables vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's LTM Mar 2026 accounts receivables of $631K is the 9th largest of the 10 companies compared; the peer median is $195.91K.
- Its year-over-year change of +5158.3% is the highest of 9, against a peer median of -6.1%.
- Accounts receivables amounts to 12.3% of revenue for LUCD, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.32M | -36.0% | +8.9% | 3.1% | |
| LTM Mar 2026 | $3.09M | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $2.42M | -48.1% | — | 7.2% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $2.04M | +224.6% | — | 17.0% |
| LTM Mar 2026 | $1.84M | -561.0% | — | 5.4% | |
| LTM Mar 2026 | $1.31M | -404.9% | — | 2.3% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.13M | +23.8% | -1.2% | 61.1% |
| LTM Mar 2026 | $1.1M | +37.9% | — | 7.3% | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $195.91K | — | — | 49.4% | |
| Peer median (excluding LUCD) | $195.91K | -6.1% | +3.8% | 7.2% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Depreciation & Amortization | 4K | 1.94M | 2.5M | 1.17M | 872K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.6M | 14.99M | 6.82M | 4.53M | 4.49M |
| Change in Working Capital | 807K | 8.91M | 5.68M | (4.43M) | (2.81M) |
| Accounts Receivables | (200K) | 183K | (28K) | 0 | (601K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (665K) | (445K) | 89K | 96K | (270K) |
| Other Working Capital | 1.67M | 9.17M | 5.61M | (4.53M) | (1.94M) |
| Other Non-Cash Items | 9.6M | 653K | 4.85M | 119K | 8.97M |
| Operating Cash Flow | (17.67M) | (29.69M) | (32.82M) | (44.14M) | (46.49M) |
| Capital Expenditures | (862K) | (908K) | (221K) | (646K) | (197K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.2M) | 0 | (350K) | 0 |
| Investing Cash Flow | (862K) | (4.11M) | (221K) | (646K) | (197K) |
| Debt Repayment | 0 | 0 | 10M | 18M | 360K |
| Common Stock Issued | 77.74M | 1.81M | 284K | 451K | 58.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.66M) | 804K | 551K | 451K | 0 |
| Financing Cash Flow | 72.08M | 2.61M | 29.46M | 48.25M | 59.03M |
| Effect of Forex Changes | (255) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 53.54M | (31.18M) | (3.58M) | 3.46M | 12.35M |
| Free Cash Flow | (18.53M) | (30.59M) | (33.04M) | (44.79M) | (46.49M) |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.